PCVX,ATHA Stock Price and Quote

Dollar change +1.41
Percentage change 2.18	%

Held by: VTI VB IWM VXF VBK IWO IBB SCHA VTWO VHT

Index	RUT	P/E	-	EPS (ttm)	-4.21	Insider Own	5.09%	Shs Outstand	108.76M	Perf Week	8.63%
Market Cap	7.17B	Forward P/E	-	EPS next Y	-4.51	Insider Trans	-5.10%	Shs Float	103.25M	Perf Month	4.10%
Income	-402.27M	PEG	-	EPS next Q	-1.13	Inst Own	91.11%	Short Float	7.98%	Perf Quarter	-12.37%
Sales	0.00M	P/S	-	EPS this Y	-2.56%	Inst Trans	6.70%	Short Ratio	11.11	Perf Half Y	37.45%
Book/sh	13.01	P/B	5.07	EPS next Y	-6.22%	ROA	-33.33%	Short Interest	8.24M	Perf Year	33.28%
Cash/sh	9.93	P/C	6.64	EPS next 5Y	-	ROE	-36.67%	52W Range	44.20 - 82.04	Perf YTD	5.03%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-46.98%	ROI	-31.86%	52W High	-19.60%	Beta	0.94
Dividend TTM	-	Quick Ratio	7.54	Sales past 5Y	0.00%	Gross Margin	-	52W Low	49.23%	ATR (14)	2.28
Dividend Ex-Date	-	Current Ratio	7.54	EPS Y/Y TTM	-22.36%	Oper. Margin	0.00%	RSI (14)	58.31	Volatility	3.75% 3.42%
Employees	254	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	103.29
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	-84.52%	Payout	-	Rel Volume	0.83	Prev Close	64.55
Sales Surprise	-	EPS Surprise	-73.56%	Sales Q/Q	-	Earnings	Feb 27 AMC	Avg Volume	742.35K	Price	65.96
SMA20	6.07%	SMA50	-1.78%	SMA200	13.90%	Trades		Volume	618,844	Change	2.18%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-07-23	Initiated	Mizuho	Buy	$69
Apr-18-23	Initiated	TD Cowen	Outperform
Jan-03-23	Reiterated	Needham	Buy	$52 → $58
Dec-15-22	Initiated	Guggenheim	Buy	$66
Nov-17-22	Initiated	BTIG Research	Buy	$69
Dec-29-21	Resumed	Jefferies	Buy	$50
Jun-24-21	Resumed	Jefferies	Buy	$50
Jul-07-20	Initiated	Needham	Buy	$40
Jul-07-20	Initiated	Cantor Fitzgerald	Overweight	$55
Jul-07-20	Initiated	BofA Securities	Buy	$37

May-04-24 02:31AM	Insider Sale at Vaxcyte Inc: COO Jim Wassil Sells 3,000 Shares (GuruFocus.com)
Apr-22-24 04:46PM	Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing (MT Newswires)
Apr-02-24 04:05PM	Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-26-24 09:02PM	Sutro Biopharma Inc (STRO) Earnings: A Mixed Bag Amidst Strategic Advances (GuruFocus.com)
Mar-20-24 07:01PM	Insider Sell: Vaxcyte Inc (PCVX) CFO Andrew Guggenhime Sells 8,000 Shares (GuruFocus.com)
08:50AM	Loading…
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-04-24 08:30AM	Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants (GlobeNewswire)
Feb-28-24 12:08PM	Q4 2023 Vaxcyte Inc Earnings Call (Thomson Reuters StreetEvents) -7.33%
12:00PM	Vaxcyte, Inc. (PCVX) Is Up 2.14% in One Week: What You Should Know (Zacks)
09:57AM	Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 04:01PM	Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-26-24 08:32AM	Why Vaxcyte (PCVX) Might Surprise This Earnings Season (Zacks)
Feb-25-24 11:05AM	5 Best Russell 2000 Stocks To Buy According To Hedge Funds (Insider Monkey)
Feb-22-24 11:28PM	Insider Sell: Vaxcyte Inc CFO Andrew Guggenhime Disposes of 8,000 Shares (GuruFocus.com)
Feb-15-24 04:05PM	Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 (GlobeNewswire)
11:12PM	Loading…
Feb-02-24 11:12PM	Director Heath Lukatch Sells 5,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com)
06:39PM	Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Feb-01-24 11:02PM	Director Heath Lukatch Sells 4,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com) +5.75%
04:05PM	Vaxcyte to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-30-24 11:37PM	Vaxcyte Announces Pricing of $750 Million Public Offering (GlobeNewswire)
04:01PM	Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jan-29-24 08:30AM	Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older (GlobeNewswire) +6.52%
Jan-19-24 08:28PM	Insider Sell: Vaxcyte Inc CFO Andrew Guggenhime Sells 8,000 Shares (GuruFocus.com)
Jan-16-24 04:01PM	Vaxcyte Appoints Whitney Jones as Chief People Officer (GlobeNewswire)
Jan-04-24 04:01PM	Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise (GlobeNewswire)
Dec-21-23 05:01PM	Insider Sell: Vaxcyte Inc CFO Andrew Guggenhime Disposes of 8,000 Shares (GuruFocus.com)
Dec-04-23 06:35PM	VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate (GlobeNewswire)
Nov-28-23 08:30AM	Vaxcyte Appoints Jacks Lee to Board of Directors (GlobeNewswire)
Nov-27-23 04:00PM	Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates (GlobeNewswire)
Nov-23-23 11:04AM	Insider Sell Alert: Vaxcyte Inc's President and CFO Andrew Guggenhime Sells 8,000 Shares (GuruFocus.com)
08:30AM	Loading…
Nov-09-23 08:30AM	Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults (GlobeNewswire) -5.06%
Nov-06-23 05:19PM	Vaxcyte Inc (PCVX) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
04:03PM	Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-03-23 11:54PM	Insider Sell: COO Jim Wassil Sells 3,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com) +6.17%
Oct-31-23 04:05PM	Vaxcyte to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-20-23 09:55PM	Insider Sell: Andrew Guggenhime Sells 8,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com)
Oct-19-23 08:30AM	Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults (GlobeNewswire)
Oct-16-23 08:00AM	Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs) (GlobeNewswire)
Oct-04-23 11:00PM	Insider Sell: Vaxcyte Inc's COO Jim Wassil Sells 3,000 Shares (GuruFocus.com)
Sep-19-23 04:05PM	Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Sep-11-23 08:21AM	Codexis (CDXS) Transfers Leasing Rights to Vaxcyte, Stock Up (Zacks)
Sep-08-23 04:44PM	Peninsula biotech grabs more space as it plans to take 2nd pneumonia vaccine into clinic (American City Business Journals)
Aug-08-23 04:03PM	Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-11-23 08:30AM	Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants (GlobeNewswire)
Jul-01-23 09:05AM	Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jun-13-23 09:30AM	5 Biotech Stocks to Buy as Industry Prospects for 2H23 Look Good (Zacks)
Jun-01-23 04:05PM	Vaxcyte to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-29-23 09:55AM	Wall Street Analysts Think Vaxcyte, Inc. (PCVX) Could Surge 33.33%: Read This Before Placing a Bet (Zacks)
May-12-23 09:55AM	Wall Street Analysts Believe Vaxcyte, Inc. (PCVX) Could Rally 26.15%: Here's is How to Trade (Zacks)
May-08-23 04:03PM	Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-03-23 04:05PM	Vaxcyte to Present at the BofA Securities 2023 Health Care Conference (GlobeNewswire) +5.21%
Apr-21-23 05:25PM	Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Apr-19-23 11:36AM	Biotech Stock Roundup: MDGL, PCVX Up on Study Data, MRNA Provides Updates (Zacks)
12:26AM	Vaxcyte Announces Pricing of $500 Million Public Offering (GlobeNewswire)
Apr-18-23 12:56PM	Vaxcyte (PCVX) Up on Pneumococcal Conjugate Vaccine Data (Zacks)
Apr-17-23 04:05PM	Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +16.00%
06:30AM	Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies (GlobeNewswire)
Apr-16-23 05:00PM	Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies (GlobeNewswire)
Mar-30-23 08:30AM	Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants (GlobeNewswire)
Mar-12-23 11:55PM	Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Feb-27-23 04:01PM	Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Feb-21-23 08:30AM	Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants (GlobeNewswire)
Feb-16-23 04:05PM	Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023 (GlobeNewswire)
Feb-07-23 04:05PM	Vaxcyte to Present at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-22-23 07:39AM	We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely (Simply Wall St.)
Jan-05-23 08:30AM	Vaxcytes VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults (GlobeNewswire)
Jan-03-23 12:34PM	This Pneumococcal Vaccine Player Is The Top Pick For 2023 For This Analyst (Benzinga)
Dec-20-22 04:05PM	Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract (GlobeNewswire)
Dec-11-22 07:21PM	TipRanks Perfect 10 List: These 3 Top-Rated Stocks Could Shine in 2023 (TipRanks)
Nov-07-22 04:10PM	Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-03-22 08:30AM	Vaxcyte to Present at Upcoming Investor Conferences (GlobeNewswire) +5.41%
Oct-31-22 02:58PM	Drugmakers Fight Over Lucrative Pneumonia Vaccines (The Wall Street Journal)
Oct-30-22 09:13AM	Vaxcyte, Inc.'s (NASDAQ:PCVX) large institutional owners must be happy as stock continues to impress, up 111% over the past week (Simply Wall St.)
Oct-29-22 11:03AM	Why Shares of Vaxcyte Rose 110.7% This Week (Motley Fool)
Oct-28-22 04:01PM	Vaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire) +5.40%
Oct-26-22 02:13PM	Vaxcyte's New Vaccine Might Beat Pfizer (TheStreet.com) +17.04%
10:55AM	First came good vaccine data. Now this company plans to raise $600 million. (American City Business Journals)
12:20AM	Vaxcyte Announces Pricing of $600 Million Public Offering (GlobeNewswire)
Oct-25-22 08:50AM	Recent Price Trend in Vaxcyte, Inc. (PCVX) is Your Friend, Here's Why (Zacks) +5.64%
Oct-24-22 05:32PM	Tricida Collapses 94%, Vaxcyte Soars as Drug Trials Diverge (Bloomberg) +60.35%
05:17PM	Vaccine developer Vaxcyte stock soars on results of experimental pneumonia jab (American City Business Journals)
04:01PM	Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
12:09PM	Vaxcyte Shares Surge As Its Pneumococcal Vaccine On Par With Pfizer's Shot In Study (Benzinga)
07:52AM	Vaxcyte's stock rallies 46% on positive data for its pneumococcal vaccine candidate (MarketWatch)
06:30AM	Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64 (GlobeNewswire)
Oct-23-22 05:00PM	Vaxcyte to Host Webcast and Conference Call to Discuss Topline Results from the Phase 1/2 Proof-of-Concept Study of VAX-24 Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults (GlobeNewswire)
Oct-11-22 04:05PM	Vaxcyte Expands Executive Leadership Team with Key Appointments (GlobeNewswire)
Sep-06-22 04:04PM	Vaxcyte Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older (GlobeNewswire)
Aug-15-22 06:27AM	We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely (Simply Wall St.)
Aug-08-22 04:15PM	Vaxcyte Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Aug-04-22 08:30AM	Vaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs (GlobeNewswire)
Jul-14-22 11:59AM	Vaxcyte (PCVX) Completes Enrollment in Pneumococcal Disease Study (Zacks)
Jul-12-22 04:05PM	Vaxcyte Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults (GlobeNewswire)
Jun-27-22 07:30PM	Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs) (PR Newswire) +5.23%
Jun-02-22 04:05PM	Vaxcyte to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-09-22 04:10PM	Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) -11.78%
May-04-22 01:34PM	Could The Vaxcyte, Inc. (NASDAQ:PCVX) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
May-03-22 08:30AM	Vaxcyte to Participate in Upcoming Investor Conferences in May (GlobeNewswire)
Apr-05-22 08:30AM	Vaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-04-22 08:30AM	Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults (GlobeNewswire) +7.10%

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	May 01 '24	Option Exercise	21.41	1,667	35,690	32,264	May 03 04:20 PM
Wassil Jim	CHIEF OPERATING OFFICER	May 01 '24	Sale	61.65	3,000	184,942	215,462	May 03 04:19 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	May 01 '24	Sale	61.70	2,616	161,419	146,054	May 03 04:18 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	May 01 '24	Sale	61.74	1,667	102,921	30,597	May 03 04:20 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Apr 23 '24	Option Exercise	1.79	15,000	26,850	492,847	Apr 25 04:52 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Apr 23 '24	Sale	61.92	15,000	928,845	477,847	Apr 25 04:52 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Apr 18 '24	Option Exercise	5.35	8,000	42,800	103,679	Apr 22 04:42 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Apr 18 '24	Sale	61.27	8,000	490,199	95,679	Apr 22 04:42 PM
Wassil Jim	CHIEF OPERATING OFFICER	Apr 17 '24	Option Exercise	5.35	3,551	18,998	221,840	Apr 19 04:31 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Apr 01 '24	Option Exercise	21.41	1,667	35,690	32,264	Apr 03 04:22 PM
Wassil Jim	CHIEF OPERATING OFFICER	Apr 01 '24	Sale	66.69	3,000	200,066	218,289	Apr 03 04:22 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Apr 01 '24	Sale	66.71	2,616	174,502	147,362	Apr 03 04:21 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Apr 01 '24	Sale	66.73	1,667	111,234	30,597	Apr 03 04:22 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Mar 25 '24	Option Exercise	1.79	15,000	26,850	492,847	Mar 27 04:44 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Mar 25 '24	Sale	66.93	15,000	1,003,978	477,847	Mar 27 04:44 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Mar 18 '24	Option Exercise	5.35	8,000	42,800	103,679	Mar 20 04:29 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Mar 18 '24	Sale	69.02	8,000	552,144	95,679	Mar 20 04:29 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Mar 11 '24	Option Exercise	2.03	65,000	131,950	477,847	Mar 13 04:22 PM
Cowan Elvia	SVP, FINANCE	Mar 01 '24	Option Exercise	25.92	11,000	285,120	24,158	Mar 04 09:22 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Mar 01 '24	Option Exercise	21.41	1,667	35,690	32,877	Mar 04 09:21 PM
Cowan Elvia	SVP, FINANCE	Mar 01 '24	Sale	74.08	11,678	865,070	12,480	Mar 04 09:22 PM
Wassil Jim	CHIEF OPERATING OFFICER	Mar 01 '24	Sale	73.71	3,000	221,134	220,852	Mar 04 09:23 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Mar 01 '24	Sale	73.70	2,616	192,799	148,670	Mar 04 09:19 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Mar 01 '24	Sale	73.73	1,667	122,907	31,210	Mar 04 09:21 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Feb 26 '24	Option Exercise	1.79	30,000	53,700	405,814	Feb 27 04:17 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Feb 26 '24	Sale	79.03	30,000	2,370,900	375,814	Feb 27 04:17 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Feb 23 '24	Option Exercise	1.79	15,000	26,850	390,814	Feb 27 04:17 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Feb 23 '24	Sale	76.21	15,000	1,143,206	375,814	Feb 27 04:17 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Feb 20 '24	Option Exercise	5.35	8,000	42,800	87,474	Feb 22 04:30 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Feb 20 '24	Sale	74.53	8,000	596,232	79,474	Feb 22 04:30 PM
Wassil Jim	CHIEF OPERATING OFFICER	Feb 15 '24	Option Exercise	2.42	27,917	67,559	203,852	Feb 20 04:22 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Feb 01 '24	Option Exercise	21.41	1,667	35,690	22,377	Feb 05 05:39 PM
Wassil Jim	CHIEF OPERATING OFFICER	Feb 01 '24	Option Exercise	2.42	3,000	7,260	178,935	Feb 05 05:37 PM
Wassil Jim	CHIEF OPERATING OFFICER	Feb 01 '24	Sale	73.88	3,000	221,626	175,935	Feb 05 05:37 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Feb 01 '24	Sale	73.91	2,616	193,353	149,978	Feb 05 05:33 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Feb 01 '24	Sale	73.87	1,667	123,144	20,710	Feb 05 05:39 PM
Lukatch Heath	Director	Jan 31 '24	Option Exercise	16.00	5,000	80,000	10,625	Feb 02 04:40 PM
Lukatch Heath	Director	Jan 31 '24	Sale	71.50	5,000	357,500	5,625	Feb 02 04:40 PM
Lukatch Heath	Director	Jan 29 '24	Option Exercise	16.00	4,000	64,000	9,625	Jan 31 04:12 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jan 29 '24	Option Exercise	1.79	30,000	53,700	405,814	Jan 31 04:11 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jan 29 '24	Sale	66.03	30,000	1,980,900	375,814	Jan 31 04:11 PM
Lukatch Heath	Director	Jan 29 '24	Sale	67.50	4,000	270,000	5,625	Jan 31 04:12 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jan 23 '24	Option Exercise	1.44	15,000	21,600	390,814	Jan 25 05:50 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jan 23 '24	Sale	63.92	15,000	958,783	375,814	Jan 25 05:50 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Jan 18 '24	Option Exercise	5.35	8,000	42,800	87,474	Jan 19 04:17 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Jan 18 '24	Sale	60.73	8,000	485,879	79,474	Jan 19 04:17 PM
Lukatch Heath	Director	Jan 02 '24	Option Exercise	16.00	13,000	208,000	18,625	Jan 04 04:26 PM
Eydelman Mikhail	SVP, Gen Counsel & Corp Sec	Jan 02 '24	Option Exercise	21.41	1,667	35,690	22,377	Jan 04 04:26 PM
Wassil Jim	Chief Operating Officer	Jan 02 '24	Option Exercise	2.42	3,000	7,260	178,935	Jan 04 04:25 PM
Lukatch Heath	Director	Jan 02 '24	Sale	63.76	13,000	828,915	5,625	Jan 04 04:26 PM
Wassil Jim	Chief Operating Officer	Jan 02 '24	Sale	63.91	3,000	191,741	175,935	Jan 04 04:25 PM
PICKERING GRANT	Chief Executive Officer	Jan 02 '24	Sale	63.89	2,616	167,144	151,286	Jan 04 04:24 PM
Eydelman Mikhail	SVP, Gen Counsel & Corp Sec	Jan 02 '24	Sale	63.93	1,667	106,579	20,710	Jan 04 04:26 PM
PICKERING GRANT	Chief Executive Officer	Dec 26 '23	Option Exercise	0.04	10,000	400	390,814	Dec 27 04:35 PM
PICKERING GRANT	Chief Executive Officer	Dec 26 '23	Sale	61.70	15,000	925,538	375,814	Dec 27 04:35 PM
PICKERING GRANT	Chief Executive Officer	Dec 22 '23	Option Exercise	2.03	9,900	20,097	380,814	Dec 27 04:35 PM
GUGGENHIME ANDREW	President and CFO	Dec 18 '23	Option Exercise	5.35	8,000	42,800	87,474	Dec 20 04:35 PM
GUGGENHIME ANDREW	President and CFO	Dec 18 '23	Sale	60.18	8,000	481,417	79,474	Dec 20 04:35 PM
GUGGENHIME ANDREW	President and CFO	Dec 14 '23	Option Exercise	5.35	14,000	74,900	93,474	Dec 18 04:01 PM
GUGGENHIME ANDREW	President and CFO	Dec 14 '23	Sale	60.22	14,000	843,080	79,474	Dec 18 04:01 PM
Eydelman Mikhail	SVP, Gen Counsel & Corp Sec	Dec 07 '23	Option Exercise	21.41	10,000	214,100	31,035	Dec 11 04:36 PM
Eydelman Mikhail	SVP, Gen Counsel & Corp Sec	Dec 07 '23	Sale	56.50	10,000	565,000	21,035	Dec 11 04:36 PM
Wassil Jim	Chief Operating Officer	Dec 01 '23	Option Exercise	2.42	3,000	7,260	178,935	Dec 05 04:16 PM
Wassil Jim	Chief Operating Officer	Dec 01 '23	Sale	52.14	3,000	156,408	175,935	Dec 05 04:16 PM
PICKERING GRANT	Chief Executive Officer	Dec 01 '23	Sale	52.12	2,618	136,442	152,594	Dec 05 04:15 PM
PICKERING GRANT	Chief Executive Officer	Nov 24 '23	Sale	49.09	15,000	736,300	370,914	Nov 28 04:50 PM
GUGGENHIME ANDREW	President and CFO	Nov 20 '23	Option Exercise	5.35	8,000	42,800	87,474	Nov 22 04:51 PM
GUGGENHIME ANDREW	President and CFO	Nov 20 '23	Sale	51.13	8,000	409,063	79,474	Nov 22 04:51 PM
Wassil Jim	Chief Operating Officer	Nov 01 '23	Option Exercise	2.42	3,000	7,260	178,935	Nov 03 04:30 PM
Wassil Jim	Chief Operating Officer	Nov 01 '23	Sale	47.26	3,000	141,778	175,935	Nov 03 04:30 PM
PICKERING GRANT	Chief Executive Officer	Nov 01 '23	Sale	47.29	2,618	123,813	153,903	Nov 03 04:29 PM
PICKERING GRANT	Chief Executive Officer	Oct 23 '23	Sale	47.07	15,000	706,070	385,914	Oct 25 04:07 PM
GUGGENHIME ANDREW	President and CFO	Oct 18 '23	Option Exercise	5.35	8,000	42,800	87,474	Oct 20 04:30 PM
GUGGENHIME ANDREW	President and CFO	Oct 18 '23	Sale	45.91	8,000	367,300	79,474	Oct 20 04:30 PM
Wassil Jim	Chief Operating Officer	Oct 12 '23	Option Exercise	2.42	5,000	12,100	175,935	Oct 16 04:21 PM
Eydelman Mikhail	SVP, Gen Counsel & Corp Sec	Oct 02 '23	Option Exercise	21.41	20,000	428,200	40,487	Oct 04 04:07 PM
Wassil Jim	Chief Operating Officer	Oct 02 '23	Option Exercise	2.42	3,000	7,260	173,935	Oct 04 04:07 PM
Eydelman Mikhail	SVP, Gen Counsel & Corp Sec	Oct 02 '23	Sale	50.40	20,000	1,007,989	20,487	Oct 04 04:07 PM
Wassil Jim	Chief Operating Officer	Oct 02 '23	Sale	50.43	3,000	151,298	170,935	Oct 04 04:07 PM
PICKERING GRANT	Chief Executive Officer	Oct 02 '23	Sale	50.42	2,618	131,996	155,212	Oct 04 04:06 PM
PICKERING GRANT	Chief Executive Officer	Sep 25 '23	Sale	52.45	15,000	786,794	400,914	Sep 27 04:54 PM
PICKERING GRANT	Chief Executive Officer	Sep 25 '23	Sale	52.43	2,618	137,264	156,521	Sep 27 04:54 PM
Wassil Jim	Chief Operating Officer	Sep 22 '23	Option Exercise	2.42	3,000	7,260	170,935	Sep 26 04:51 PM
Wassil Jim	Chief Operating Officer	Sep 01 '23	Option Exercise	2.42	3,000	7,260	173,066	Sep 06 05:33 PM
Wassil Jim	Chief Operating Officer	Sep 01 '23	Sale	52.82	3,000	158,447	170,066	Sep 06 05:33 PM

PCVX

Vaxcyte Inc

ATHA

Athira Pharma Inc

Upgrade your FINVIZ experience